Paclitaxel News and Research

RSS
Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.
Study estimates the cost-effectiveness of therapeutic alternatives

Study estimates the cost-effectiveness of therapeutic alternatives

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Chemo-immunotherapy combination shows promise against pancreatic cancer

Chemo-immunotherapy combination shows promise against pancreatic cancer

Study finds no difference in survival between patients treated with paclitaxel drug-coated devices and non-DCDs

Study finds no difference in survival between patients treated with paclitaxel drug-coated devices and non-DCDs

Study could provide a new approach to treating metastatic triple negative breast cancer

Study could provide a new approach to treating metastatic triple negative breast cancer

Study shows superiority of Chocolate Touch device for opening blocked arteries in the leg

Study shows superiority of Chocolate Touch device for opening blocked arteries in the leg

Study: Ketogenic diet helps kill pancreatic cancer cells when combined with a triple-drug therapy

Study: Ketogenic diet helps kill pancreatic cancer cells when combined with a triple-drug therapy

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

BAK/MCL1 complex in tumor cells can predict the sensitivity of chemotherapy drugs in ovarian cancer

BAK/MCL1 complex in tumor cells can predict the sensitivity of chemotherapy drugs in ovarian cancer

New genetic classifier can predict the sensitivity of neoadjuvant chemotherapy for breast cancer

New genetic classifier can predict the sensitivity of neoadjuvant chemotherapy for breast cancer

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

Innovative testing platform could enable more precise, personalized immunotherapy

Innovative testing platform could enable more precise, personalized immunotherapy

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

SWOG researchers to present practice-changing research at virtual ASCO 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices